echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > eClinicalMed: Efficacy of the novel Bruton tyrosine kinase inhibitor Orelabrutinib in the treatment of relapsed/refractory Waldenström macroglobulinemia

    eClinicalMed: Efficacy of the novel Bruton tyrosine kinase inhibitor Orelabrutinib in the treatment of relapsed/refractory Waldenström macroglobulinemia

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Orelabrutinib is a novel small molecule selective irreversible Bruton tyrosine kinase inhibitor


    This is a prospective, multicenter clinical trial that enrolled patients with R/R WM who



    Between August 2019 and December 2020, a total of 66 patients with



    For patients with MYD88L265P/CXCR4NEG, MYD88L265P/CXCR4S338X, or MYD88NEG/CXCR4NEG mutations, MRR was 84.


    Most of the adverse reactions were grade 1-2 (91.


    In summary, Orelabrutinib has demonstrated good efficacy and controlled safety


    Original Source:

    Xin-xin Cao, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.